Join Our Compensated
Depression Study
Depression Study
Researchers at Johns Hopkins are recruiting older adults for a research study to learn more about changes in the brain that occur with depression and Parkinson's Disease.
55-75 Years Old
Within 50 miles of Baltimore, MD
Symptoms of Depression
With or Without Parkinson's Disease
Compensation Provided
Fast Facts
About This Study
This research is being done to understand the changes in brain chemistry associated with depression in late life and with the response to antidepressant medication.
Study participants will visit the Johns Hopkins Medical Institution for an initial screening, brain scans, and mood and mental function tests. Participants experiencing depression will receive treatment with a drug called Vortioxetine (also known as Trintellix), and treatment will be monitored by the study psychiatrist.
Vortioxetine (Trintellix) is an antidepressant associated with improvement in mood and cognition, particularly in patients who do not respond to SSRIs.
Further research on how depression impacts the brain and join our compensated study today!
IRB Protocol No: IRB00269869 [May 11, 2023]
Principal Investigator: Gwenn S. Smith, PhD
Study participants will visit the Johns Hopkins Medical Institution for an initial screening, brain scans, and mood and mental function tests. Participants experiencing depression will receive treatment with a drug called Vortioxetine (also known as Trintellix), and treatment will be monitored by the study psychiatrist.
Vortioxetine (Trintellix) is an antidepressant associated with improvement in mood and cognition, particularly in patients who do not respond to SSRIs.
Further research on how depression impacts the brain and join our compensated study today!
IRB Protocol No: IRB00269869 [May 11, 2023]
Principal Investigator: Gwenn S. Smith, PhD
About This Study This research is being done to understand the changes in brain chemistry associated with depression in late life and with the response to antidepressant medication. Study participants will visit the Johns Hopkins Medical Institution for an initial screening, brain scans, and mood and mental function tests. Participants experiencing depression will receive treatment with a drug called Vortioxetine (also known as Trintellix), and treatment will be monitored on a weekly basis by the study psychiatrist. Vortioxetine (Trintellix) is an antidepressant associated with improvement in mood and cognition, particularly in patients who do not respond to SSRIs. Further research on how depression impacts the brain and join our compensated study today! IRB Protocol No: IRB00269869 [May 11, 2023] Principal Investigator: Gwenn S. Smith, PhD |
Additional Information
The purpose of the study is to understand changes in the brain chemical serotonin that are associated with depression and the effects of the antidepressant medication Vortioxetine (Trintellix).
You may qualify for this study if you meet the following criteria.
Inclusion Criteria:
Inclusion Criteria:
- Currently experiencing symptoms of depression
- Between the ages of 55-75
- Live within 50 miles of Baltimore
- Generally healthy with or without Parkinson's Disease
- Eligible for an MRI scan
- No history of adverse reactions to SSRIs
- The entire study will last about 12 weeks.
- Participants will make 5 visits to complete the baseline clinical evaluations, lab work, memory testing, and brain scans.
- During the course of the study, your treatment will be monitored.
- At the end of the study, the memory testing and brain scans will be repeated.
Qualified individuals will be compensated for their time. The study medication will be provided to you. Transportation will also be provided.
Qualified individuals will participate at no cost.
If you need immediate medical attention, please call 911 or go to the nearest emergency room.